Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.612
Buy
RSI(14)
84.889
Overbought
STOCH(KDJ)(9,3,3)
76.298
Neutral
ATR(14)
0.720
High Vlolatility
CCI(14)
184.262
Buy
Williams %R
21.392
Buy
TRIX(12,20)
6.432
Buy
StochRSI(14)
78.351
Buy
NovaBay Pharmaceuticals Inc
NBY5.250USD
+2.300+77.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
31.56MMarket Cap
0.85P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of NovaBay Pharmaceuticals Inc
Currency: USD Updated: 2025-12-19Key Insights
NovaBay Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 133/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 0.85.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NovaBay Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.850
Target Price
-18.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NovaBay Pharmaceuticals Inc Highlights
StrengthsRisks
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78M.
Overvalued
The company’s latest PE is 0.85, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.37M shares, decreasing 5.68% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 84.49K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.07.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of NovaBay Pharmaceuticals Inc is 6.30, ranking 146/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 521.00K, representing a year-over-year decrease of 78.66%, while its net profit experienced a year-over-year decrease of 41.68%.
Score
Financials
9.45
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.03
Operational Efficiency
4.99
Growth Potential
2.18
Shareholder Returns
6.87
NovaBay Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of NovaBay Pharmaceuticals Inc is 4.94, ranking 155/158 in the Pharmaceuticals industry. Its current P/E ratio is 0.85, which is 21.46% below the recent high of 1.04 and 2769.40% above the recent low of -22.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 133/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19No earnings forecast score is currently available for NovaBay Pharmaceuticals Inc. The Pharmaceuticals industry's average is 7.80. The average price target for NovaBay Pharmaceuticals Inc is 0.85, with a high of 0.85 and a low of 0.85.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of NovaBay Pharmaceuticals Inc is 6.06, ranking 131/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.56 and the support level at 1.95, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.524
Buy
MA10
2.901
Buy
MA20
1.965
Buy
MA50
1.460
Buy
MA100
1.282
Buy
MA200
0.838
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of NovaBay Pharmaceuticals Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 22.81%, representing a quarter-over-quarter decrease of 6.95%. The largest institutional shareholder is The Vanguard, holding a total of 84.49K shares, representing 0.07% of shares outstanding, with 900.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Poplar Point Capital Management LLC
Geode Capital Management, L.L.C.
Tower Research Capital LLC
Freiman (Paul Edward)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of NovaBay Pharmaceuticals Inc is 1.04, ranking 154/158 in the Pharmaceuticals industry. The company's beta value is 0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.06
VaR
+8.94%
240-Day Maximum Drawdown
+69.11%
240-Day Volatility
+168.95%
Return
Best Daily Return
60 days
+79.66%
120 days
+79.66%
5 years
+79.66%
Worst Daily Return
60 days
-17.95%
120 days
-27.61%
5 years
-64.06%
Sharpe Ratio
60 days
+3.34
120 days
+3.21
5 years
-0.29
Risk Assessment
Maximum Drawdown
240 days
+69.11%
3 years
+99.54%
5 years
+99.98%
Return-to-Drawdown Ratio
240 days
+16.61
3 years
-0.30
5 years
-0.20
Skewness
240 days
+3.57
3 years
+2.66
5 years
+2.75
Volatility
Realised Volatility
240 days
+168.95%
5 years
+152.03%
Standardised True Range
240 days
+2.32%
5 years
+299.82%
Downside Risk-Adjusted Return
120 days
+812.30%
240 days
+812.30%
Maximum Daily Upside Volatility
60 days
+284.22%
Maximum Daily Downside Volatility
60 days
+79.47%
Liquidity
Average Turnover Rate
60 days
+113.25%
120 days
+57.54%
5 years
--
Turnover Deviation
20 days
-6.87%
60 days
-67.83%
120 days
-83.66%
Peer Comparison
Pharmaceuticals
NovaBay Pharmaceuticals Inc
NBY
3.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of NovaBay Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of NovaBay Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of NovaBay Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of NovaBay Pharmaceuticals Inc?
To generate the financial health score of NovaBay Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects NovaBay Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of NovaBay Pharmaceuticals Inc.
How do we generate the company valuation score of NovaBay Pharmaceuticals Inc?
To generate the company valuation score of NovaBay Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare NovaBay Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of NovaBay Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of NovaBay Pharmaceuticals Inc.
How do we generate the earnings forecast score of NovaBay Pharmaceuticals Inc?
To calculate the earnings forecast score of NovaBay Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on NovaBay Pharmaceuticals Inc’s future.
How do we generate the price momentum score of NovaBay Pharmaceuticals Inc?
When generating the price momentum score for NovaBay Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of NovaBay Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for NovaBay Pharmaceuticals Inc.
How do we generate the institutional confidence score of NovaBay Pharmaceuticals Inc?
To generate the institutional confidence score of NovaBay Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about NovaBay Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of NovaBay Pharmaceuticals Inc.
How do we generate the risk management score of NovaBay Pharmaceuticals Inc?
To assess the risk management score of NovaBay Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of NovaBay Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of NovaBay Pharmaceuticals Inc.
